Insulin inhalation - Eli Lilly/Dura Pharmaceuticals

Drug Profile

Insulin inhalation - Eli Lilly/Dura Pharmaceuticals

Latest Information Update: 20 Jun 2001

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dura Pharmaceuticals
  • Developer Dura Pharmaceuticals; Eli Lilly
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 24 Jul 2013 Biomarkers information updated
  • 20 Jun 2001 Discontinued-II for Type-1 diabetes mellitus in USA (Inhalation)
  • 20 Jun 2001 Discontinued-II for Type-2 diabetes mellitus in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top